- Home
- OBE vs LENZ Comparison
OBE vs LENZ Comparison
Compare OBE & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | LENZ |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.8M | 609.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OBE | LENZ |
|---|---|---|
| Price | $7.42 | $13.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $56.25 |
| AVG Volume (30 Days) | 560.6K | ★ 1.1M |
| Earning Date | 02-19-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $441,312,666.00 | $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $194.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.88 | $12.48 |
| 52 Week High | $8.10 | $50.40 |
Technical Indicators
Market Signals| Indicator | OBE | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 55.44 | 31.24 |
| Support Level | $7.25 | $12.48 |
| Resistance Level | $7.55 | $21.80 |
| Average True Range (ATR) | 0.40 | 1.22 |
| MACD | -0.01 | -0.24 |
| Stochastic Oscillator | 50.15 | 9.43 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.